Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.

The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor ...

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...

Krystal Biotech (NASDAQ:KRYS) said it has generated positive interim clinical results for its inhaled cystic fibrosis (CF) ...

PITTSBURGH - Krystal Biotech, Inc. (NASDAQ:KRYS) announced Thursday that its experimental gene therapy KB407 successfully delivered and expressed wild-type CFTR protein in the lungs of cystic fibrosis ...

The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives ...

Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has proven itself as a long-term winner. 10 stocks we like ...

4D Molecular Therapeutics (4DMT) is pressing ahead with evaluation of its gene therapy, 4D-710, in a Phase II dose expansion trial in cystic fibrosis (CF) after the drug displayed positive ...